{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:13:10Z","timestamp":1793833990154,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.phrs.2025.108045","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:53:23Z","timestamp":1764143603000},"page":"108045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["History of glucagon-like peptide-1 receptor agonists"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3419-4118","authenticated-orcid":false,"given":"Radwan","family":"Darwish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghena","family":"Abu-Sharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-3917","authenticated-orcid":false,"given":"Alexandra E.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.phrs.2025.108045_bib1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108045_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12933-021-01258-x","article-title":"Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study","volume":"20","author":"Lugner","year":"2021","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"10.1016\/j.phrs.2025.108045_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1113\/jphysiol.1902.sp000920","article-title":"The mechanism of pancreatic secretion","volume":"28","author":"Bayliss","year":"1902","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2025.108045_bib4","unstructured":"Labarre J.-F., editor Sur les possibilites d\u2032un traitement du diabete par I\u2032incretine1932."},{"issue":"12","key":"10.1016\/j.phrs.2025.108045_bib5","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1172\/JCI105685","article-title":"Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects","volume":"46","author":"Perley","year":"1967","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.phrs.2025.108045_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/00365521.1970.12096632","article-title":"A multiparameter study on the action of preparations containing cholecystokinin-pancreozymin","volume":"5","author":"Brown","year":"1970","journal-title":"Scand. J. Gastroenterol."},{"issue":"5924","key":"10.1016\/j.phrs.2025.108045_bib7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2025.108045_bib8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.phrs.2025.108045_bib9","first-page":"952","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","volume":"80","author":"Deacon","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.phrs.2025.108045_bib10","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1016\/S0021-9258(17)37366-0","article-title":"Structure-activity studies of glucagon-like peptide-1","volume":"269","author":"Adelhorst","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.phrs.2025.108045_bib11","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.phrs.2025.108045_bib12","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2025.108045_bib13","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.phrs.2025.108045_bib14","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.phrs.2025.108045_bib15","first-page":"281","article-title":"Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus","volume":"19","author":"Bond","year":"2006","journal-title":"Proc. (Bayl. Univ. Med Cent. )"},{"issue":"18","key":"10.1016\/j.phrs.2025.108045_bib16","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.108045_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front.Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108045_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.phrs.2025.108045_bib19","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)","volume":"38","author":"Giorgino","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.phrs.2025.108045_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"10.1016\/j.phrs.2025.108045_bib21","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108045_bib22","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.phrs.2025.108045_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALe diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.phrs.2025.108045_bib24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.ahj.2013.07.012","article-title":"Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial","volume":"166","author":"Marso","year":"2013","journal-title":"Am. Heart J."},{"issue":"19","key":"10.1016\/j.phrs.2025.108045_bib25","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2025.108045_bib26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.phrs.2025.108045_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.108045_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"issue":"10295","key":"10.1016\/j.phrs.2025.108045_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.phrs.2025.108045_bib30","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/clinem\/dgae038","article-title":"Tirzepatide improved markers of islet cell function and insulin sensitivity in people with T2D (SURPASS-2)","volume":"109","author":"Frias","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2025.108045_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10366","key":"10.1016\/j.phrs.2025.108045_bib32","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","volume":"400","author":"Urva","year":"2022","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.phrs.2025.108045_bib33","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"Pt B","key":"10.1016\/j.phrs.2025.108045_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models","volume":"136","author":"Holscher","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.108045_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"24","key":"10.1016\/j.phrs.2025.108045_bib36","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.phrs.2025.108045_bib37","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2025.108045_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"Pt 3","key":"10.1016\/j.phrs.2025.108045_bib39","article-title":"Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders: a large-scale propensity-matched cohort study","volume":"143","author":"Siddeeque","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2025.108045_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/nu17081303","article-title":"Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review","volume":"17","author":"Gofron","year":"2025","journal-title":"Nutrients"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T23:48:31Z","timestamp":1766188111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"alternative-id":["S1043661825004700"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108045","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"History of glucagon-like peptide-1 receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108045"}}